Dose-effect relationship of stereotactic body radiotherapy in non-small cell lung cancer patients

被引:7
作者
Li, Fei [1 ]
Jiang, Hairong [2 ]
Bu, Mingwei [3 ]
Mu, Xin [4 ]
Zhao, Hongfu [1 ]
机构
[1] Jilin Univ, China Japan Union Hosp, Dept Radiat Oncol, 126,Xiantai St, Changchun 130033, Jilin, Peoples R China
[2] Jilin City Hosp Chem Ind, Dept Geriatr, Jilin 130022, Jilin, Peoples R China
[3] Changchun Hosp, Guowen Med Corp, Dept Radiat Oncol, Changchun 130028, Jilin, Peoples R China
[4] Jilin City Hosp Chem Ind, Dept Radiat Oncol, Jilin 130022, Jilin, Peoples R China
关键词
Non-small cell lung cancer; Stereotactic body radiotherapy; Dose-effect relationship; PHASE-II TRIAL; LOCAL TUMOR-CONTROL; RADIATION-THERAPY; ABLATIVE RADIOTHERAPY; SBRT; OUTCOMES; VOLUME; EXPERIENCE; CARCINOMA; SURVIVAL;
D O I
10.1186/s13014-022-02183-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To establish the dose effect relationship between the dose parameters of stereotactic body radiation therapy (SBRT) for early non-small cell lung cancer (NSCLC) and the local tumor control rate. Materials and methods: A comprehensive literature search was conducted using PubMed, the Web of Science and the Cochrane databases to determine the articles treated with SBRT in early-stage NSCLC. Original studies with complete prescription dose information, tumor local control rate and other important parameters were screened and reported. Probit model in XLSTAT 2016 was used for regression analysis, and P < 0.05 was set as a statistically significant level. Results: After literature screening, 22 eligible studies were included in probit model regression analysis, involving 1861 patients. There is no significant dose effect relationship between nominal BED10 and peripheral BED10 versus 3 years local control probability. There were significant dose effect relationships between the center BED10 and the average BED10 versus the 3 years local control probability, with P values are 0.001 and < 0.0001, respectively. According to the results of this model, the 3 years local control rate of 90.5% (87.5-92.1%) and 89.5% (86.7-91.0%) can be expected at the center BED10 of 180 Gy or the average BED10 of 140 Gy, prospectively. Conclusions: For NSCLC treated with SBRT, more attention should be paid to the central dose and average dose of PTV. A set of clear definition in the dose prescription should be established to ensure the effectiveness and comparability of treatment.
引用
收藏
页数:10
相关论文
共 45 条
[1]   Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size [J].
Baba, Fumiya ;
Shibamoto, Yuta ;
Ogino, Hiroyuki ;
Murata, Rumi ;
Sugie, Chikao ;
Iwata, Hiromitsu ;
Otsuka, Shinya ;
Kosaki, Katsura ;
Nagai, Aiko ;
Murai, Taro ;
Miyakawa, Akifumi .
RADIATION ONCOLOGY, 2010, 5
[2]   Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy [J].
Baumann, Pia ;
Nyman, Jan ;
Hoyer, Morten ;
Wennberg, Berit ;
Gagliardi, Giovanna ;
Lax, Ingmar ;
Drugge, Ninni ;
Ekberg, Lars ;
Friesland, Signe ;
Johansson, Karl-Axel ;
Lund, Jo-Asmund ;
Morhed, Elisabeth ;
Nilsson, Kristina ;
Levin, Nina ;
Paludan, Merete ;
Sederholm, Christer ;
Traberg, Anders ;
Wittgren, Lena ;
Lewensohn, Rolf .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3290-3296
[3]   Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial [J].
Bezjak, Andrea ;
Paulus, Rebecca ;
Gaspar, Laurie E. ;
Timmerman, Robert D. ;
Straube, William L. ;
Ryan, William F. ;
Garces, Yolanda I. ;
Pu, Anthony T. ;
Singh, Anurag K. ;
Videtic, Gregory M. ;
McGarry, Ronald C. ;
Iyengar, Puneeth ;
Pantarotto, Jason R. ;
Urbanic, James J. ;
Sun, Alexander Y. ;
Daly, Megan E. ;
Grills, Inga S. ;
Sperduto, Paul ;
Normolle, Daniel P. ;
Bradley, Jeffrey D. ;
Choy, Hak .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15) :1316-+
[4]   Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients [J].
Ceniceros, L. ;
Aristu, J. ;
Castanon, E. ;
Rolfo, C. ;
Legaspi, J. ;
Olarte, A. ;
Valtuena, G. ;
Moreno, M. ;
Gil-Bazo, I. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (03) :259-268
[5]   Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery [J].
Chang, Joe Y. ;
Mehran, Reza J. ;
Feng, Lei ;
Verma, Vivek ;
Liao, Zhongxing ;
Welsh, James W. ;
Lin, Steven H. ;
O'Reilly, Michael S. ;
Jeter, Melenda D. ;
Balter, Peter A. ;
McRae, Stephen E. ;
Berry, Donald ;
Heymach, John, V ;
Roth, Jack A. .
LANCET ONCOLOGY, 2021, 22 (10) :1448-1457
[6]   Comparison of Single- and Five-fraction Regimens of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-small-cell Lung Cancer: A Two-institution Propensity-matched Analysis [J].
Cummings, Michael A. ;
Ma, Sung Jun ;
Hermann, Gregory ;
Serra, Lucas ;
Syed, Yusef ;
Malhotra, Harish K. ;
Chen, Yuhchyau ;
Milano, Michael T. ;
Gomez-Suescun, Jorge A. ;
Singh, Deepinder P. ;
Singh, Anurag K. .
CLINICAL LUNG CANCER, 2018, 19 (06) :511-517
[7]   An Analysis of Clinical Toxic Effects and Quality of Life as a Function of Radiation Dose and Volume After Lung Stereotactic Body Radiation Therapy [J].
Devpura, Suneetha ;
Feldman, Aharon M. ;
Rusu, Samuel D. ;
Mayyas, Essa ;
Movsas, Avielle ;
Brown, Stephen L. ;
Cook, Andrew ;
Simoff, Michael J. ;
Sun, Zhen ;
Lu, Mei ;
Vance, Sean ;
Ajlouni, Munther, I ;
Siddiqui, M. Salim ;
Chetty, Indrin J. ;
Movsas, Benjamin .
ADVANCES IN RADIATION ONCOLOGY, 2021, 6 (06)
[8]   Relationship between Dose Prescription Methods and Local Control Rate in Stereotactic Body Radiotherapy for Early Stage Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis [J].
Eriguchi, Takahisa ;
Takeda, Atsuya ;
Nemoto, Takafumi ;
Tsurugai, Yuichiro ;
Sanuki, Naoko ;
Tateishi, Yudai ;
Kibe, Yuichi ;
Akiba, Takeshi ;
Inoue, Mari ;
Nagashima, Kengo ;
Horita, Nobuyuki .
CANCERS, 2022, 14 (15)
[9]   STEREOTACTIC BODY RADIATION THERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CARCINOMA: FOUR-YEAR RESULTS OF A PROSPECTIVE PHASE II STUDY [J].
Fakiris, Achilles J. ;
McGarry, Ronald C. ;
Yiannoutsos, Constantin T. ;
Papiez, Lech ;
Williams, Mark ;
Henderson, Mark A. ;
Timmerman, Robert .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03) :677-682
[10]   Outcomes After Stereotactic Lung Radiotherapy or Wedge Resection for Stage I Non-Small-Cell Lung Cancer [J].
Grills, Inga S. ;
Mangona, Victor S. ;
Welsh, Robert ;
Chmielewski, Gary ;
McInerney, Erika ;
Martin, Shannon ;
Wloch, Jennifer ;
Ye, Hong ;
Kestin, Larry L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) :928-935